## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.1% in lower entry zone (3.0-6.0%), top quartile (89th pct) cross-sectional ranking. Short-term MRS_5 (0.1%) confirms momentum alignment. Strong momentum (+2.4% 5-day acceleration). Outperforming sector by 4.1%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($331.75)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 1, Bearish: 5)

**1. Bronstein, Gewirtz & Grossman, LLC Is Investigating Elevance Health, Inc. (ELV) And Encourages Shareholders to Connect**
- Source: MyStateline | 20251214T160757 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elevance Health, Inc. (NYSE:ELV). The investigation focuses on whether Elevance and its officers engaged in corporate wrongdoing, particularly for investors who bought securities before April 18, 2024, and still hold them. The firm encourages affected shareholders to connect through their website to assist in the investigation.

**2. Bronstein, Gewirtz & Grossman, LLC Is Investigating Elevance Health, Inc. (ELV) And Encourages Shareholders to Connect**
- Source: FOX 8 News | 20251214T160753 | Somewhat-Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Elevance Health, Inc. (ELV) for potential corporate wrongdoing, focusing on actions prior to April 18, 2024. The firm encourages shareholders who purchased Elevance securities before this date and still hold them to connect for more information and to assist in the investigation. The representation is on a contingency fee basis with no upfront cost to investors.

**3. Anthem Blue Cross and Blue Shield Foundation Awards More Than $1M to Support Maternal Health Programs Across Virginia**
- Source: Business Wire | 20251215T175207 | Bullish | Relevance: 100%
- The Anthem Blue Cross and Blue Shield Foundation has granted over $1 million to five Virginia nonprofits to enhance maternal health outcomes. These organizations—Urban Baby Beginnings, United Way Southwest Virginia, March of Dimes, Richmond Behavioral Health Foundation, and HumanKind—will utilize the funds for programs promoting healthier pregnancies, stronger families, and improved access to care across the state. This initiative aims to close health gaps and foster healthier futures for women and children in Virginia.

**4. Liontrust Investment Partners LLP Reduces Stock Position in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251215T112319 | Neutral | Relevance: 100%
- Liontrust Investment Partners LLP reduced its stake in Elevance Health, Inc. by 24.4% in the second quarter, selling 7,272 shares and ending with 22,510 shares valued at approximately $8.76 million. Other institutional investors have also adjusted their positions in the company. Elevance Health recently beat quarterly earnings estimates and declared a quarterly dividend of $1.71.

**5. National Bank of Canada FI Trims Stock Holdings in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251215T102419 | Somewhat-Bullish | Relevance: 100%
- National Bank of Canada FI reduced its stake in Elevance Health (NYSE:ELV) by 9.9% in Q2, selling nearly 20,000 shares but still holding 181,798 shares valued at approximately $70.7 million. Despite institutional investors owning 89.24% of the stock, analysts maintain a "Moderate Buy" rating with an average target price of $400.83. Elevance Health recently surpassed quarterly earnings estimates, reported strong revenue, and declared a $1.71 quarterly dividend.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-26 | TD Cowen | $400 | $380 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-26 | TD Cowen | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +2.4% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.04 suggests fair value with growth premium. Analyst sentiment positive (1 raises, avg +5%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $79.2B |
| Beta | 0.53 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.04 |
| Forward P/E | 13.0 |
| Current P/E | 11.7 |
| YoY Growth | -9.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 1.8% to 4.1% (+2.4% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 89th percentile. MRS_5 at 0.1% confirms short-term momentum alignment. Outperforming sector by 4.1pp, stock-specific strength. Below SMA200 (0.98x), long-term trend not supportive. MACD histogram positive (3.10), confirming momentum. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.11% (CS: 89) | Strong |
| RSI_14 | 60.9 | Neutral |
| MACD Histogram | 3.10 | Bullish |
| vs SMA20 | 1.049x | Above |
| vs SMA50 | 1.048x | Above |
| vs SMA200 | 0.985x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $351.87
- **Stop Loss:** $331.75 (5.7% risk)
- **Target:** $382.05 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 49
- **Position Value:** $17,241.63
- **Portfolio %:** 17.24%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*